BCL2 and B-cell chronic lymphocytic leukemia: Early clinical trial data were promising, indicating that sonrotoclax was well tolerated and achieved good responses both as monotherapy340 and in combination with zanubrutinib in R/R and treatment naïve CLL/SLL.341,342 BGB-21447 is another BCL2 inhibitor, for which there are no published data, however there is a phase I clinical trial in mature B cell malignancies underway (NCT05828589).